GlassScriptPhysician profile
Anne B Spencer
NPI 1699927111
$4,363.11
in general payments reported to CMS, 2019-2025
45 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $616 · 2021: $824 · 2022: $493 · 2023: $575 · 2024: $680 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $546.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $477.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $407.72 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $362.15 | 2019-2025 | Saphnelo, Airsupra, Farxiga |
| Pfizer INC. | $292.11 | 2020-2025 | |
| Amgen INC. | $290.88 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.49 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $168.44 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $156.76 | 2019-2024 | Proclaim, Freestyle Libre 2, Octrode |
| Takeda Pharmaceuticals U.S.A., INC. | $132.10 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.40 | 2019-2022 | |
| Astellas Pharma US INC | $105.73 | 2019-2024 | Veozah |
| Allergan, INC. | $89.70 | 2019-2020 | |
| Cmp Pharma, INC. | $83.78 | 2022 | |
| Amarin Pharma, INC. | $64.38 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.